The single financial pane of truth — P&L, quality of earnings, profitability, FP&A and segment economics.
Margin is recovering (Q4 exited at 15.3% — a 14-quarter high), but ≈ ₹339 Cr of EBITDA still sits between the 12.8% full-year margin and the 15% target — held in commodity-films spreads and the value-added mix shift. Convert the mix (33% → 40%) and the films-cycle recovery into reported EBITDA to fund deleverage and re-rate the stock.
6 of 8 headline metrics improving vs prior · still off target: Revenue from Operations ₹15,401 Cr vs ₹16,500 Cr, Revenue Growth (YoY) 2.4% vs 7.0%, Contribution Margin 41.6% vs 44.0%
Hold FY27 capex ≤ ₹1,400 Cr, sweep OCF to debt as commissioned assets ramp — deleverage is the goal, not the achievement.
Net debt ₹8,622 Cr = 4.35× EBITDA, up from 3.73× (peak 4.52× in Q3); headroom to the 5.5× ceiling is ~1.15×.
Each day of DSO ties up ~₹42 Cr of working capital that could fund the FY27 debt paydown.
≈ ₹339 Cr of EBITDA stands between the 12.8% full-year margin and the 15% target — the swing that funds deleverage and re-rates the listed equity (Q4 exit 15.3% shows the path).
Tighten CPG terms & export-doc cycles; factor overseas receivables selectively; target DSO 75.
DSO 92 days, inventory ~97 days; AR ₹3,882 Cr with ₹700 Cr >60d overdue.
How ₹15,401 Cr of revenue converts to ₹1,984 Cr reported EBITDA (12.8%).
| Revenue | ₹15,401 Cr | 100.0% |
| COGS — resins & inputs (crude-linked) | (₹8,994 Cr) | (58.4%) |
| Contribution | ₹6,407 Cr | 41.6% |
| Conversion & other opex (personnel, power & fuel, freight) | (₹3,098 Cr) | (20.1%) |
| SG&A / overheads | (₹1,324 Cr) | (8.6%) |
| EBITDA (reported) | ₹1,984 Cr | 12.9% |
The two real definitions — normalized ₹1,910 Cr (12.3%) plus net FX / derivative gains of ₹74 Cr = reported ₹1,984 Cr (12.8%), the cockpit KPI.
Value-added growth (+18%) and the films-spread recovery vs. the FX / derivative swing and films realizations & cost-push (BOPET glut, GST 2.0 destocking, West Asia freight).
Forecast discipline, program realization (mix / circularity / working capital) and productivity.
Margin journey and program capture by business — from launch margin to today's ₹ Cr EBITDA contribution (lenses overlap; not additive to the group).
| Business / line | Since | Revenue | Value-added | EBITDA (launch % → ₹Cr now) | Program capture | Status |
|---|---|---|---|---|---|---|
| Flexible Packaging (Laminates & Pouches) | 1988 | ₹3,389 Cr | ₹3,100 Cr | 12% → ₹542 Cr | 84% | Integrated |
| Flex Films (Global Films) | 1994 | ₹9,093 Cr | ₹480 Cr | 18% → ₹955 Cr | 78% | Integrated |
| UFlex Engineering & Cylinders | 1995 | ₹448 Cr | ₹0 Cr | 9% → ₹54 Cr | 70% | In progress |
| UFlex Holography & Security | 1999 | ₹380 Cr | ₹380 Cr | 14% → ₹68 Cr | 80% | Integrated |
| Flexcure / Flexgreen (Chemicals & Inks) | 2004 | ₹791 Cr | ₹0 Cr | 10% → ₹103 Cr | 72% | In progress |
| Asepto (Aseptic Liquid Packaging) | 2017 | ₹1,300 Cr | ₹1,300 Cr | 6% → ₹234 Cr | 76% | In progress |
| F-TPM / F-WSP (Specialty Films) | 2019 | ₹420 Cr | ₹139 Cr | 12% → ₹71 Cr | 66% | In progress |
| Asclepius (90% PCR Film) | 2023 | ₹240 Cr | ₹150 Cr | 8% → ₹34 Cr | 58% | In progress |
One click into the owning view — each reads the same live governed dataset.